Frank Himmelsbach

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

Systems Biology, Medicine, Bronchial Neoplasm +8

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Flavio Solca, G. Dahl, Andreas Zoephel et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 848 citations

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 583 citations

8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

Matthias Eckhardt, Elke Langkopf, Michael Mark et al. · Journal of Medicinal Chemistry · 2007 · 281 citations · Full text

Pharmaceutical Science, Xanthine Scaffold, Pharmacotherapy +17

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

Leo Thomas, Matthias Eckhardt, Elke Langkopf et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 277 citations